截至6月30日，英诺特股东户数7269.00，较上期减少2.94%；人均流通股9466股，较上期增加3.03%。 2025年1月-6月，英诺特实现营业收入2.76亿元，同比减少34.35%；归母净利润1.25亿元，同比减少 39.36%。 分红方面，英诺特A股上市后累计派现1.52亿元。 责任编辑：小浪快报 8月28日，英诺特跌0.75%，成交额1.01亿元。两融数据显示，当日英诺特获融资买入额1931.28万元， 融资偿还2225.23万元，融资净买入-293.95万元。截至8月28日，英诺特融资融券余额合计2.13亿元。 融资方面，英诺特当日融资买入1931.28万元。当前融资余额2.13亿元，占流通市值的9.73%，融资余额 低于近一年50%分位水平，处于较低位。 融券方面，英诺特8月28日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元；融 券余量0.00股，融券余额0.00元，超过近一年70%分位水平，处于较高位。 资料显示，北京英诺特生物技术股份有限公司位于北京市丰台区海鹰路1号院6号楼1层2层、2号楼7层， 成立日期2006年2月6日，上市日期2022年7月28日，公 ...

Group 1 - The core viewpoint of the article highlights that Innotech's stock closed at 31.5 yuan, down 1.25%, with a rolling PE ratio of 21.92 times and a total market capitalization of 4.298 billion yuan [1] - Innotech operates in the bioproducts industry, which has an average PE ratio of 57.79 times and a median of 38.07 times, placing Innotech at the 34th position in the industry ranking [1] - As of the first quarter of 2025, four institutions held shares in Innotech, with a total of 5.2561 million shares valued at 183 million yuan [1] Group 2 - Innotech's main business focuses on the research, production, and sales of POCT rapid diagnostic products, primarily targeting respiratory pathogen detection, while also covering areas such as reproductive health, digestive tract, and hepatitis testing [1] - The latest performance report for the first quarter of 2025 shows that Innotech achieved an operating revenue of 207 million yuan, a year-on-year decrease of 26.51%, and a net profit of 95.2897 million yuan, down 34.77%, with a gross profit margin of 83.12% [1]